Kiniksa Pharmaceuticals L... (KNSA)
Kiniksa Pharmaceuticals Statistics
Share Statistics
Kiniksa Pharmaceuticals has 72.95M shares outstanding. The number of shares has increased by 2.4% in one year.
| Shares Outstanding | 72.95M |
| Shares Change (YoY) | 2.4% |
| Shares Change (QoQ) | 0.61% |
| Owned by Institutions (%) | 54.61% |
| Shares Floating | 69.7M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 3.13M, so 4.31% of the outstanding shares have been sold short.
| Short Interest | 3.13M |
| Short % of Shares Out | 4.31% |
| Short % of Float | 9.56% |
| Short Ratio (days to cover) | 6.16 |
Valuation Ratios
The PE ratio is -32.71 and the forward PE ratio is 16.3. Kiniksa Pharmaceuticals's PEG ratio is 0.08.
| PE Ratio | -32.71 |
| Forward PE | 16.3 |
| PS Ratio | 3.34 |
| Forward PS | 1.3 |
| PB Ratio | 3.22 |
| P/FCF Ratio | 55.59 |
| PEG Ratio | 0.08 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Kiniksa Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.3, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.3 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | 0.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.34M |
| Profits Per Employee | $-137.12K |
| Employee Count | 315 |
| Asset Turnover | 0.73 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 7.04M |
| Effective Tax Rate | -19.48% |
Stock Price Statistics
The stock price has increased by 19.52% in the last 52 weeks. The beta is 0.31, so Kiniksa Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.31 |
| 52-Week Price Change | 19.52% |
| 50-Day Moving Average | 21.04 |
| 200-Day Moving Average | 22.51 |
| Relative Strength Index (RSI) | 44.56 |
| Average Volume (20 Days) | 639.1K |
Income Statement
In the last 12 months, Kiniksa Pharmaceuticals had revenue of 423.24M and earned -43.19M in profits. Earnings per share was -0.6.
| Revenue | 423.24M |
| Gross Profit | 423.24M |
| Operating Income | -45.62M |
| Net Income | -43.19M |
| EBITDA | -45.62M |
| EBIT | -45.62M |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has 183.58M in cash and 9.86M in debt, giving a net cash position of 173.73M.
| Cash & Cash Equivalents | 183.58M |
| Total Debt | 9.86M |
| Net Cash | 173.73M |
| Retained Earnings | -521.14M |
| Total Assets | 580.55M |
| Working Capital | 231.18M |
Cash Flow
In the last 12 months, operating cash flow was 25.69M and capital expenditures -277K, giving a free cash flow of 25.41M.
| Operating Cash Flow | 25.69M |
| Capital Expenditures | -277K |
| Free Cash Flow | 25.41M |
| FCF Per Share | 0.36 |
Margins
Gross margin is 100%, with operating and profit margins of -10.78% and -10.21%.
| Gross Margin | 100% |
| Operating Margin | -10.78% |
| Pretax Margin | -8.54% |
| Profit Margin | -10.21% |
| EBITDA Margin | -10.78% |
| EBIT Margin | -10.78% |
| FCF Margin | 6% |
Dividends & Yields
KNSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for KNSA is $37.5, which is 85.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.5 |
| Price Target Difference | 85.6% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 5.98 |
| Piotroski F-Score | 4 |